Advanced search
Publication Cover
Leukemia & Lymphoma Volume 54, 2013 - Issue 10
Submit an article Journal homepage
1,047
Views
71
CrossRef citations to date
0
Altmetric
Research Article

Modeling progression risk for smoldering multiple myeloma: results from a prospective clinical study

Benjamin M. CherryMultiple Myeloma Section, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
,
Neha KordeMultiple Myeloma Section, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
,
Mary KwokMultiple Myeloma Section, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA;Walter Reed National Military Medical Center, Bethesda, MD, USA
,
Elisabet E. ManasanchMultiple Myeloma Section, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
,
Manisha BhutaniMultiple Myeloma Section, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
,
Marcia MulquinMultiple Myeloma Section, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
,
Diamond ZuchlinskiMultiple Myeloma Section, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
,
Mary Ann YanceyMultiple Myeloma Section, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
,
Irina MaricHematology Service, Department of Laboratory Medicine, NIH, Bethesda, MD, USA
,
Katherine R. CalvoHematology Service, Department of Laboratory Medicine, NIH, Bethesda, MD, USA
,
Raul BraylanHematology Service, Department of Laboratory Medicine, NIH, Bethesda, MD, USA
,
Maryalice Stetler-StevensonLaboratory of Pathology, Center for Cancer Research, NCI, NIH, Bethesda, MD, USA
,
Constance YuanLaboratory of Pathology, Center for Cancer Research, NCI, NIH, Bethesda, MD, USA
,
Prashant TembhareLaboratory of Pathology, Center for Cancer Research, NCI, NIH, Bethesda, MD, USA
,
Adriana ZingoneMultiple Myeloma Section, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
,
Rene CostelloMultiple Myeloma Section, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
,
Mark J. RoschewskiMultiple Myeloma Section, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
&
Ola LandgrenMultiple Myeloma Section, National Cancer Institute, National Institutes of Health, Bethesda, MD, USACorrespondence[email protected].
 show all
Pages 2215-2218 | Received 05 Sep 2012, Accepted 03 Jan 2013, Published online: 29 Jul 2013

Citations (71)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (12)

Morie Gertz. (2022) Smoldering multiple myeloma: Reviewing the rationale for intervention. Leukemia & Lymphoma 63:9, pages 2033-2040.
Read now
Chutima Kunacheewa & Elisabet E. Manasanch. (2021) The benefits of early intervention using lenalidomide for high-risk smoldering multiple myeloma: emerging data and its promising clinical impact. Expert Review of Hematology 14:12, pages 1059-1069.
Read now
Morie A Gertz & Iuliana Vaxman. (2021) Should high risk smoldering myeloma be treated outside a clinical trial: NO. Leukemia & Lymphoma 62:11, pages 2565-2567.
Read now
Matthew Ho, Giada Bianchi & Kenneth C. Anderson. (2020) Proteomics-inspired precision medicine for treating and understanding multiple myeloma. Expert Review of Precision Medicine and Drug Development 5:2, pages 67-85.
Read now
Federica Cocito, Silvia Mangiacavalli, Virginia Valeria Ferretti, Claudio Salvatore Cartia, Maya Ganzetti, Pietro Benveuti, Alessandra Pompa, Martina Catalano, Elena Fugazza, Benedetta Landini, Luca Arcaini & Alessandro Corso. (2019) Smoldering multiple myeloma: the role of different scoring systems in identifying high-risk patients in real-life practice. Leukemia & Lymphoma 60:12, pages 2968-2974.
Read now
Agnieszka Blum, Despina Bazou & Peter O’Gorman. (2018) Smoldering multiple myeloma: prevalence and current evidence guiding treatment decisions. Blood and Lymphatic Cancer: Targets and Therapy 8, pages 21-31.
Read now
Eli Muchtar, Shaji K. Kumar, Hila Magen & Morie A. Gertz. (2018) Diagnosis and management of smoldering multiple myeloma: the razor’s edge between clonality and cancer. Leukemia & Lymphoma 59:2, pages 288-299.
Read now
Sham Mailankody, Sean M. Devlin, Neha Korde, Nikoletta Lendvai, Alexander Lesokhin, Heather Landau, Hani Hassoun, Andrea Ballagi, Daniel Ekman, David J. Chung, Minal Patel, Guenther Koehne, Sergio Giralt & Ola Landgren. (2017) Proteomic profiling in plasma cell disorders: a feasibility study. Leukemia & Lymphoma 58:7, pages 1757-1759.
Read now
Karma Z Salem & Irene M Ghobrial. (2015) The road to cure in multiple myeloma starts with smoldering disease. Expert Opinion on Orphan Drugs 3:6, pages 653-661.
Read now
Elisabet E. Manasanch, Dalia A. Salem, Constance M. Yuan, Nishant Tageja, Manisha Bhutani, Mary Kwok, Dickran Kazandjian, George Carter, Seth M. Steinberg, Diamond Zuchlinski, Marcia Mulquin, Katherine Calvo, Irina Maric, Mark Roschewski, Neha Korde, Raul Braylan, Ola Landgren & Maryalice Stetler-Stevenson. (2015) Flow cytometric sensitivity and characteristics of plasma cells in patients with multiple myeloma or its precursor disease: influence of biopsy site and anticoagulation method. Leukemia & Lymphoma 56:5, pages 1416-1424.
Read now
Adewale Fawole, Rafat Abonour, Michael Stender, Seerin Shatavi, Susanna Gaikazian, Joseph Anderson & Ishmael Jaiyesimi. (2015) Is it time for preemptive drug treatment of asymptomatic (smoldering) multiple myeloma?. Leukemia & Lymphoma 56:1, pages 34-41.
Read now
María-Victoria Mateos. (2015) Management of asymptomatic myeloma patients. Expert Review of Hematology 8:1, pages 19-27.
Read now

Articles from other publishers (59)

Laura Notarfranchi, Roberta Segreto, Rosanna Vescovini, Anna Benedetta Dalla Palma, Valentina Marchica, Jessica Burroughs‐Garcia, Denise Toscani, Giannalisa Todaro, Vincenzo Raimondi, Nicolas Thomas Iannozzi, Sabrina Bonomini, Gabriella Sammarelli, Luisa Craviotto, Mario Pedrazzoni, Paola Storti & Nicola Giuliani. (2022) The impact of CD56 expression in smoldering myeloma patients on early progression. Hematological Oncology 41:3, pages 587-589.
Crossref
Shin Young Yun, John Hoon Rim, Hak Park, Hyein Kang, Sang-Guk Lee & Jong-Baeck Lim. (2023) Clinical implication by differential analytical performances of serum free light chain quantitation analysis using fully automated analyzers. Clinical Chemistry and Laboratory Medicine (CCLM) 61:7, pages 1288-1299.
Crossref
Iuliana Vaxman & Morie A. Gertz. (2022) How I approach smoldering multiple myeloma. Blood 140:8, pages 828-838.
Crossref
Benjamin Derman, Jorge J. Castillo, Shayna Sarosiek & Meral Beksac. (2022) When a Monoclonal Gammopathy Is Not Multiple Myeloma. American Society of Clinical Oncology Educational Book:42, pages 655-664.
Crossref
Louise Ainley, Marquita Camilleri, Selina J. Chavda, Annabel McMillan, Lydia Lee, Rakesh Popat, Francesca Sillito & Kwee Yong. (2021) Applying current smouldering myeloma risk models to a UK single‐centre cohort and clinical features at progression. British Journal of Haematology 196:6.
Crossref
Hashim Mann, Vatsala Katiyar, Cindy Varga & Raymond L. Comenzo. (2022) Smoldering multiple myeloma – Past, present, and future. Blood Reviews 52, pages 100869.
Crossref
Tyler Lussier, Natalie Schoebe & Sabine Mai. (2021) Risk Stratification and Treatment in Smoldering Multiple Myeloma. Cells 11:1, pages 130.
Crossref
Bénedith Oben, Guy Froyen, Kylee H. Maclachlan, Daniel Leongamornlert, Federico Abascal, Binbin Zheng-Lin, Venkata Yellapantula, Andriy Derkach, Ellen Geerdens, Benjamin T. Diamond, Ingrid Arijs, Brigitte Maes, Kimberly Vanhees, Malin Hultcrantz, Elisabet E. Manasanch, Dickran Kazandjian, Alexander Lesokhin, Ahmet Dogan, Yanming Zhang, Aneta Mikulasova, Brian Walker, Gareth Morgan, Peter J. Campbell, Ola Landgren, Jean-Luc Rummens, Niccolò Bolli & Francesco Maura. (2021) Whole-genome sequencing reveals progressive versus stable myeloma precursor conditions as two distinct entities. Nature Communications 12:1.
Crossref
Ignacio Isola, David F. Moreno, Esther Moga, Mari-Pau Mena, Natalia Tovar, Luis Gerardo Rodríguez-Lobato, Aina Oliver-Caldés, M. Carmen Salgado, Fara Brasó-Maristany, Jordi Yagüe, M. Teresa Cibeira, Aleix Prat, Laura Rosiñol, Joan Bladé & Carlos Fernández de Larrea. (2021) Immunoparesis defined by heavy/light chain pair suppression in smoldering multiple myeloma shows initial isotype specificity and involves other isotypes in advanced disease. Annals of Hematology 100:12, pages 2997-3005.
Crossref
Charlotte Gran, Vincent Luong, Johanna B. Bruchfeld, Johan Liwing, Gabriel Afram, Johan Lund, Saad Usmani, Evren Alici & Hareth Nahi. (2020) Dynamic follow‐up of smoldering multiple myeloma identifies a subset of patients at high risk of progression. American Journal of Hematology 96:3.
Crossref
Aaron M. GoodmanMyung S. Kim & Vinay Prasad. (2021) Persistent challenges with treating multiple myeloma early. Blood 137:4, pages 456-458.
Crossref
Behrang Amini, Yves-Paul N. Nakache, Lorenzo Nardo, Elisabet E. Manasanch, Jia Sun, Leon Lenchik & Robert D. Boutin. (2020) Marrow uptake on FDG PET/CT is associated with progression from smoldering to symptomatic multiple myeloma. Skeletal Radiology 50:1, pages 79-85.
Crossref
Matthew Ho, Ashish Patel, Chia Yin Goh, Maria Moscvin, Li Zhang & Giada Bianchi. (2020) Changing paradigms in diagnosis and treatment of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM). Leukemia 34:12, pages 3111-3125.
Crossref
Rasmus Sørrig. (2020) Serum markers alone can define high‐risk smouldering multiple myeloma: new insights from the Czech Myeloma Group model. British Journal of Haematology 190:2, pages 137-138.
Crossref
E. Bridget Kim, Andrew J. Yee & Noopur Raje. (2020) Treatment of Smoldering Multiple Myeloma: Ready for Prime Time?. Cancers 12:5, pages 1223.
Crossref
Rafael Fonseca & Miguel Gonzalez-Velez. (2020) Treatment of Smoldering Multiple Myeloma: Expectant Observation Should Still Be the Standard. American Society of Clinical Oncology Educational Book:40, pages 364-370.
Crossref
Oliver C. Lomas & Irene M. Ghobrial. (2020) Clinical Controversies in the Management of Smoldering Multiple Myeloma. American Society of Clinical Oncology Educational Book:40, pages 314-319.
Crossref
Sagar Lonial, Susanna Jacobus, Rafael Fonseca, Matthias Weiss, Shaji Kumar, Robert Z. Orlowski, Jonathan L. Kaufman, Abdulraheem M. Yacoub, Francis K. Buadi, Timothy O’Brien, Jeffrey V. Matous, Daniel M. Anderson, Robert V. Emmons, Anuj Mahindra, Lynne I. Wagner, Madhav V. Dhodapkar & S. Vincent Rajkumar. (2020) Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma. Journal of Clinical Oncology 38:11, pages 1126-1137.
Crossref
Francesco Maura, Niccolò Bolli, Even H. Rustad, Malin Hultcrantz, Nikhil Munshi & Ola Landgren. (2020) Moving From Cancer Burden to Cancer Genomics for Smoldering Myeloma. JAMA Oncology 6:3, pages 425.
Crossref
Niccolo Bolli, Elisa Genuardi, Bachisio Ziccheddu, Marina Martello, Stefania Oliva & Carolina Terragna. (2020) Next-Generation Sequencing for Clinical Management of Multiple Myeloma: Ready for Prime Time?. Frontiers in Oncology 10.
Crossref
Chutima Kunacheewa & Elisabet E. Manasanch. (2020) High-risk smoldering myeloma versus early detection of multiple myeloma: Current models, goals of therapy, and clinical implications. Best Practice & Research Clinical Haematology, pages 101152.
Crossref
Mattia D'Agostino, Luca Bertamini, Stefania Oliva, Mario Boccadoro & Francesca Gay. (2019) Pursuing a Curative Approach in Multiple Myeloma: A Review of New Therapeutic Strategies. Cancers 11:12, pages 2015.
Crossref
Puglisi, Parrinello, Giallongo, Cambria, Camiolo, Bellofiore, Conticello, Fabro, Leotta, Markovic, Sapienza, Barbato, Scalese, Tibullo, Brundo, Palumbo, * Romano. (2019) Plasticity of High-Density Neutrophils in Multiple Myeloma is Associated with Increased Autophagy via STAT3. International Journal of Molecular Sciences 20:14, pages 3548.
Crossref
Muhammad Usman Munir, Ayesha Ihsan, Ibrahim Javed, M. Tayyab Ansari, Sadia Z. Bajwa, Syed Nasir Abbas Bukhari, Arsalan Ahmed, M. Zubair Malik & Waheed S. Khan. (2019) Controllably Biodegradable Hydroxyapatite Nanostructures for Cefazolin Delivery against Antibacterial Resistance. ACS Omega 4:4, pages 7524-7532.
Crossref
Elizabeth Hill, Alex Dew & Dickran Kazandjian. (2019) State of the science in smoldering myeloma: Should we be treating in the clinic?. Seminars in Oncology 46:2, pages 112-120.
Crossref
Prashant Kapoor & S. Vincent Rajkumar. (2019) Smoldering Multiple Myeloma. The Cancer Journal 25:1, pages 65-71.
Crossref
Hedley Coleman, Jos Hille, Willie van Heerden, Sonja Boy & Annabelle Mahar. 2019. Contemporary Oral Medicine. Contemporary Oral Medicine 555 626 .
Shaji K. Kumar. (2018) Timing of treatment of smoldering myeloma: delay until progression. Blood Advances 2:21, pages 3050-3053.
Crossref
Carlos Fernández de Larrea, Ignacio Isola, Arturo Pereira, Ma Teresa Cibeira, Laura Magnano, Natalia Tovar, Luis-Gerardo Rodríguez-Lobato, Xavier Calvo, Juan I. Aróstegui, Tania Díaz, Ester Lozano, María Rozman, Jordi Yagüe, Joan Bladé & Laura Rosiñol. (2018) Evolving M-protein pattern in patients with smoldering multiple myeloma: impact on early progression. Leukemia 32:6, pages 1427-1434.
Crossref
Hedley Coleman, Jos Hille, Willie van Heerden, Sonja Boy & Annabelle Mahar. 2018. Contemporary Oral Medicine. Contemporary Oral Medicine 1 73 .
Ola Landgren. (2017) Shall we treat smoldering multiple myeloma in the near future?. Hematology 2017:1, pages 194-204.
Crossref
Nicola Maciocia, Ashutosh Wechalekar & Kwee Yong. (2017) Monoclonal gammopathy of undetermined significance (MGUS) and smoldering myeloma (SMM): a practical guide to management. Hematological Oncology 35:4, pages 432-439.
Crossref
Sham MailankodyDickran KazandjianNeha KordeMark RoschewskiElisabet ManasanchManisha BhutaniNishant TagejaMary KwokYong ZhangAdriana ZingoneLaurence LamyRene CostelloCandis MorrisonMalin HultcrantzAustin ChristoffersonMegan WashingtonMartin BoatengSeth M. Steinberg, Maryalice Stetler-StevensonWilliam D. FiggElli Papaemmanuil, Wyndham H. WilsonJonathan J. KeatsOla Landgren. (2017) Baseline mutational patterns and sustained MRD negativity in patients with high-risk smoldering myeloma. Blood Advances 1:22, pages 1911-1918.
Crossref
Viera Sandeck?, Roman H?jek, Lud?k Pour, Ivan ?pi?ka, Vlastimil ??udla, Ev?en Gregora, Jakub Radocha, Lenka Walterov?, Petr Kessler, Lenka Zahradov?, Dagmar Adamov?, Kamila Valentova, Ivan Vonke, Jarmila Obernauerov?, David Starostka, Marek Wr?bel, Lucie Bro?ov?, Ji?? Jarkovsk?, Aneta Mikul??ov?, Lucie ??hov?, Sabina ?ev??kov?, J?n Straub, Ji?? Mina??k, Zden?k Adam, Marta Krej??, Zden?k Kr?l & Vladim?r Maisnar. (2017) A first Czech analysis of 1887 cases with monoclonal gammopathy of undetermined significance. European Journal of Haematology 99:1, pages 80-90.
Crossref
N Lee, S Y Moon, J-h Lee, H-K Park, S-Y Kong, S-M Bang, J H Lee, S-S Yoon & D S Lee. (2017) Discrepancies between the percentage of plasma cells in bone marrow aspiration and BM biopsy: Impact on the revised IMWG diagnostic criteria of multiple myeloma. Blood Cancer Journal 7:2, pages e530-e530.
Crossref
Madhav V. Dhodapkar. (2016) MGUS to myeloma: a mysterious gammopathy of underexplored significance. Blood 128:23, pages 2599-2606.
Crossref
Siyang Leng & Suzanne Lentzsch. (2016) High-risk smoldering myeloma: Perspective on watchful monitoring. Seminars in Oncology 43:6, pages 697-699.
Crossref
Inhye E. Ahn & Sham Mailankody. (2016) Controversies in multiple myeloma: Evidence-based update. Seminars in Oncology 43:6, pages 666-675.
Crossref
Rasmus S?rrig, Tobias W. Klausen, Morten Salomo, Annette J. Vangsted, Brian ?stergaard, Henrik Gregersen, Ulf Christian Fr?lund, Niels F. Andersen, Carsten Helleberg, Kristian T. Andersen, Robert S. Pedersen, Per Pedersen, Niels Abildgaard & Peter Gimsing. (2016) Smoldering multiple myeloma risk factors for progression: a Danish population-based cohort study. European Journal of Haematology 97:3, pages 303-309.
Crossref
P Ravi, S Kumar, J T Larsen, W Gonsalves, F Buadi, M Q Lacy, R Go, A Dispenzieri, P Kapoor, J A Lust, D Dingli, Y Lin, S J Russell, N Leung, M A Gertz, R A Kyle, P L Bergsagel & S V Rajkumar. (2016) Evolving changes in disease biomarkers and risk of early progression in smoldering multiple myeloma. Blood Cancer Journal 6:7, pages e454-e454.
Crossref
Salomon ManierKarma Z. SalemDavid LiuIrene M. Ghobrial. (2016) Future Directions in the Evaluation and Treatment of Precursor Plasma Cell Disorders. American Society of Clinical Oncology Educational Book:36, pages e400-e406.
Crossref
Jo Caers, Carlos Fernández de Larrea, Xavier Leleu, Roy Heusschen, Niklas Zojer, Olivier Decaux, Efstathios Kastritis, Monique Minnema, Artur Jurczyszyn, Yves Beguin, Ralph Wäsch, Antonio Palumbo, Meletios Dimopoulos, Maria Victoria Mateos, Heinz Ludwig & Monika Engelhardt. (2016) The Changing Landscape of Smoldering Multiple Myeloma: A European Perspective. The Oncologist 21:3, pages 333-342.
Crossref
Guy Pratt, Stella Bowcock, Andrew Chantry, Gordon Cook, Graham Jackson, Maggie Lai, Eric Low, Nicola Mulholland, Roger Owen, Neil Rabin, Karthik Ramasamy, John A Snowden, Matthew Streetly, Ashutosh Wechalekar, Kwee Yong & Jenny Bird. (2015) Time to redefine Myeloma. British Journal of Haematology 171:1, pages 1-10.
Crossref
S. Vincent Rajkumar, Ola Landgren & María-Victoria Mateos. (2015) Smoldering multiple myeloma. Blood 125:20, pages 3069-3075.
Crossref
H. Quach, D. Joshua, J. Ho, J. Szer, A. Spencer, S. Harrison, P. Mollee, A. Roberts, N. Horvath, D. Talaulikar, B. To, A. Zannettino, R. Brown, L. Catley, B. Augustson, W. Jaksic, J. Gibson & H. M. Prince. (2015) Treatment of patients with multiple myeloma who are not eligible for stem cell transplantation: position statement of the myeloma foundation of Australia Medical and Scientific Advisory Group. Internal Medicine Journal 45:3, pages 335-343.
Crossref
A J Waxman, R Mick, A L Garfall, A Cohen, D T Vogl, E A Stadtmauer & B M Weiss. (2014) Classifying ultra-high risk smoldering myeloma. Leukemia 29:3, pages 751-753.
Crossref
Inhye E. AhnSham MailankodyNeha KordeOla Landgren. (2015) Dilemmas in Treating Smoldering Multiple Myeloma. Journal of Clinical Oncology 33:1, pages 115-123.
Crossref
J Bae, R Prabhala, A Voskertchian, A Brown, C Maguire, P Richardson, G Dranoff, K C Anderson & N C Munshi. (2014) A multiepitope of XBP1, CD138 and CS1 peptides induces myeloma-specific cytotoxic T lymphocytes in T cells of smoldering myeloma patients. Leukemia 29:1, pages 218-229.
Crossref
Irene M. Ghobrial & Ola Landgren. (2014) How I treat smoldering multiple myeloma. Blood 124:23, pages 3380-3388.
Crossref
S Vincent Rajkumar, Meletios A Dimopoulos, Antonio Palumbo, Joan Blade, Giampaolo Merlini, María-Victoria Mateos, Shaji Kumar, Jens Hillengass, Efstathios Kastritis, Paul Richardson, Ola Landgren, Bruno Paiva, Angela Dispenzieri, Brendan Weiss, Xavier LeLeu, Sonja Zweegman, Sagar Lonial, Laura Rosinol, Elena Zamagni, Sundar Jagannath, Orhan Sezer, Sigurdur Y Kristinsson, Jo Caers, Saad Z Usmani, Juan José Lahuerta, Hans Erik Johnsen, Meral Beksac, Michele Cavo, Hartmut Goldschmidt, Evangelos Terpos, Robert A Kyle, Kenneth C Anderson, Brian G M Durie & Jesus F San Miguel. (2014) International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. The Lancet Oncology 15:12, pages e538-e548.
Crossref
Adriana Zingone, Weixin Wang, Meghan Corrigan-Cummins, S. Peter Wu, Ryan Plyler, Neha Korde, Mary Kwok, Elisabet E. Manasanch, Nishant Tageja, Manisha Bhutani, Marcia Mulquin, Diamond Zuchlinski, Mary Ann Yancey, Mark Roschewski, Yong Zhang, Aldo M. Roccaro, Irene M. Ghobrial, Katherine R. Calvo & Ola Landgren. (2014) Altered cytokine and chemokine profiles in multiple myeloma and its precursor disease. Cytokine 69:2, pages 294-297.
Crossref
Claire Bories & Sundar Jagannath. (2014) Asymptomatic Monoclonal Gammopathies. Clinical Lymphoma Myeloma and Leukemia 14, pages S78-S86.
Crossref
Neha Korde, Sham Mailankody & Ola Landgren. (2014) The Road to Treating Smoldering Multiple Myeloma. Clinical Lymphoma Myeloma and Leukemia 14, pages S59-S64.
Crossref
Ola Landgren & Gareth J. Morgan. (2014) Biologic Frontiers in Multiple Myeloma: From Biomarker Identification to Clinical Practice. Clinical Cancer Research 20:4, pages 804-813.
Crossref
Madhav V. DhodapkarRachael SextonSarah Waheed, Saad Usmani, Xenofon Papanikolaou, Bijay Nair, Nathan Petty, John D. ShaughnessyJrJr, Antje HoeringJohn CrowleyRobert Z. Orlowski & Bart Barlogie. (2014) Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120). Blood 123:1, pages 78-85.
Crossref
Nishant Tageja, Elisabet E. Manasanch, Neha Korde, Mary Kwok, Sham Mailankody, Manisha Bhutani, Mark Roschewski & Ola Landgren. (2014) Smoldering multiple myeloma: present position and potential promises. European Journal of Haematology 92:1, pages 1-12.
Crossref
María-Victoria MateosJesús F San Miguel. (2013) Asymptomatic (smoldering) myeloma: treatment strategy. International Journal of Hematologic Oncology 2:6, pages 445-453.
Crossref
María-Victoria Mateos & Jesús F. San Miguel. (2013) New Approaches to Smoldering Myeloma. Current Hematologic Malignancy Reports 8:4, pages 270-276.
Crossref
. (2013) Treatment for High-Risk Smoldering Myeloma. New England Journal of Medicine 369:18, pages 1762-1765.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.